Changes in Beneficial Ownership · 4
ProKidney Corp.
PROKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-04
- Issuer
- PROKIDNEY CORP.
- Issuer CIK
- 0001850270
- Trading symbol
- PROK
Reporting owner 1
- Name
- Pereira Brian JG
- Reporting owner CIK
- 0001298146
- Relationship
- Director
- Address
- C/O PROKIDNEY CORP, 2000 FRONTIS PLAZA BLVD, SUITE 250, WINSTON SALEM, NC, 27103
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-08-04 | C · Form 4 | 81,929 | A | 0 | 81,929 | D | |
| Class A Common Stock | 2026-08-04 | C · Form 4 | 675,235 | A | 0 | 675,235 | I | By Brian J. G. Pereira 2012 Irrevocable Trust |
Table key
- C · Form 4
- Derivative conversion
- A
- Acquired
- D
- Direct
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Class B Common Stock[F1] | 0 | 2026-08-04 | C · Form 4 | 81,929 | D | 0 | [F2] | [F2] | Class A Common Stock | 81,929 | 0 | D | |
| Common Units in ProKidney Holdings, LLC | 0 | 2026-08-04 | C · Form 4 | 81,929 | D | 0 | [F3] | [F3] | Class A Common Stock | 81,929 | 0 | D | |
| Class B Common Stock[F1] | 0 | 2026-08-04 | C · Form 4 | 675,235 | D | 0 | [F2] | [F2] | Class A Common Stock | 675,235 | 0 | I | By Brian J. G. Pereira 2012 Irrevocable Trust |
| Common Units in ProKidney Holdings, LLC | 0 | 2026-08-04 | C · Form 4 | 675,235 | D | 0 | [F3] | [F3] | Class A Common Stock | 675,235 | 0 | I | By Brian J. G. Pereira 2012 Irrevocable Trust |
Table key
- C · Form 4
- Derivative conversion
- D
- Disposed
- I
- Indirect
Footnotes
- F1
- The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis.↩ 1↩ 2
- F2
- The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire.↩ 1↩ 2↩ 3↩ 4
Signature 1
- Signed
- /s/ Todd Girolamo, attorney in fact
- Date
- 2026-08-06
Company context
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.